Literature DB >> 22227410

Comment to: "Spontaneous transformation of adult mesenchymal stem cells from cynomolgus macaques in vitro" by Z. Ren et al. Exp. Cell Res. 317 (2011) 2950-2957: spontaneous transformation of mesenchymal stem cells in culture: facts or fiction?

Anja Torsvik1, Gro V Røsland, Rolf Bjerkvig.   

Abstract

There is at present a controversy in the literature whether MSCs are susceptible to spontaneous in vitro transformation or not. Several groups have reported spontaneous transformation of MSCs from various species. However, some of these reports were not true transformations and later proven to be due to cross-contaminating cancer cells. To date there is no solid evidence that MSCs can undergo spontaneous transformation in culture. Only two groups used DNA fingerprinting to authenticate their transformed cells, and both groups later showed cross-contamination of cancer cells in their cultures. In this commentary, we address the paper "Spontaneous transformation of adult mesenchymal stem cells from cynomolgus macaques in vitro" by Z. Ren et al. Exp. Cell Res. 317 (2011) 2950-2957. In this article the authors characterize the transformed mesenchymal cells (TMCs) and claim to have verified their origin. We question the authentication of the TMCs made by the authors and we also believe it is in the interest of the scientific community, that a highly controversial finding, such as spontaneous transformation of MSCs, should be properly verified by stringent methods, preferably DNA fingerprinting, in order to validate if an actual transformation event has occurred. Copyright Â
© 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22227410     DOI: 10.1016/j.yexcr.2011.12.009

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  8 in total

1.  Guidelines for the use of cell lines in biomedical research.

Authors:  R J Geraghty; A Capes-Davis; J M Davis; J Downward; R I Freshney; I Knezevic; R Lovell-Badge; J R W Masters; J Meredith; G N Stacey; P Thraves; M Vias
Journal:  Br J Cancer       Date:  2014-08-12       Impact factor: 7.640

2.  Safety of mesenchymal stem cells for clinical application.

Authors:  Youwei Wang; Zhi-Bo Han; Yong-Ping Song; Zhong Chao Han
Journal:  Stem Cells Int       Date:  2012-05-16       Impact factor: 5.443

Review 3.  Mesenchymal Stromal Cell Therapeutic Delivery: Translational Challenges to Clinical Application.

Authors:  Henry Caplan; Scott D Olson; Akshita Kumar; Mitchell George; Karthik S Prabhakara; Pamela Wenzel; Supinder Bedi; Naama E Toledano-Furman; Fabio Triolo; Julian Kamhieh-Milz; Guido Moll; Charles S Cox
Journal:  Front Immunol       Date:  2019-07-31       Impact factor: 7.561

Review 4.  Age-associated changes in the ecological niche: implications for mesenchymal stem cell aging.

Authors:  Faizal Z Asumda
Journal:  Stem Cell Res Ther       Date:  2013-05-14       Impact factor: 6.832

5.  Long-term cultured mesenchymal stem cells frequently develop genomic mutations but do not undergo malignant transformation.

Authors:  Y Wang; Z Zhang; Y Chi; Q Zhang; F Xu; Z Yang; L Meng; S Yang; S Yan; A Mao; J Zhang; Y Yang; S Wang; J Cui; L Liang; Y Ji; Z-B Han; X Fang; Z C Han
Journal:  Cell Death Dis       Date:  2013-12-05       Impact factor: 8.469

6.  Human umbilical cord-derived mesenchymal stem cells do not undergo malignant transformation during long-term culturing in serum-free medium.

Authors:  Gecai Chen; Aihuan Yue; Zhongbao Ruan; Yigang Yin; RuZhu Wang; Yin Ren; Li Zhu
Journal:  PLoS One       Date:  2014-06-02       Impact factor: 3.240

7.  Treatment of vocal fold scarring with autologous bone marrow-derived human mesenchymal stromal cells-first phase I/II human clinical study: commentary to response.

Authors:  Stellan Hertegård; Katarina LeBlanc
Journal:  Stem Cell Res Ther       Date:  2020-06-16       Impact factor: 6.832

Review 8.  Mesenchymal Stromal Cells Based Therapy in Systemic Sclerosis: Rational and Challenges.

Authors:  Juliette Peltzer; Marc Aletti; Nadira Frescaline; Elodie Busson; Jean-Jacques Lataillade; Christophe Martinaud
Journal:  Front Immunol       Date:  2018-09-13       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.